Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
March 2015
-
Media ReleaseNovartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancerJakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
-
Turning up the heat on tumors
-
Media ReleaseNovartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
-
Vision hacker
Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.
-
Let there be sight
-
Media ReleaseFDA approves first biosimilar ZarxioTM (filgrastim-sndz) from SandozSandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Media ReleaseNovartis announces completion of transactions with GSKCompletes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
-
Media ReleaseNovartis gibt Abschluss von Transaktionen mit GSK bekanntMit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
-
Media ReleaseNovartis annonce la conclusion des transactions avec GSKConclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
February 2015
-
Media ReleasePositive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degenerationPhase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Novartis Board of DirectorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administrationLes actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
Pagination
- ‹ Previous page
- 1
- …
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- …
- 152
- › Next page